3. Anemia Therapy I: Erythropoiesis-Stimulating Agents
Published Online: 4 JUL 2012
Copyright © 2013 John Wiley & Sons, Ltd.
Basics of Blood Management, Second edition
How to Cite
Seeber, P. and Shander, A. (2012) Anemia Therapy I: Erythropoiesis-Stimulating Agents, in Basics of Blood Management, Second edition, Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781118338070.ch3
- Published Online: 4 JUL 2012
- Published Print: 24 AUG 2012
Print ISBN: 9780470670705
Online ISBN: 9781118338070
- Erythropoietin hyporesponsiveness;
- Adjuvant therapy;
- Anabolic steroids;
Erythropoiesis-stimulating agents are one of the three cornerstones for anemia therapy. When administered judiciously, they not only increase red cell mass, but can also improve outcome. However, if used unrestrictedly, they may harm patients, e.g., by modulating the patient's risk for thromboembolic events and promotion of cancer growth. This chapter explains the use of generic recombinant erythropoietin and how practically to overcome obstacles to successful erythropoietin therapy such as erythropoietin resistance. It also describes other erythropoiesis-stimulating agents, such as darbepoetin, CERA, hematide or anabolic steroids, and their potential.